Sunday, October 23, 2011 8:57:28 PM
SNDY .0011 another low float play, on watch.
o/s 304,897,710 according to this post http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67975300
float 70,416,215 (need confirmation)
a/s 500,000,000
Recent News
BOSTON, Oct. 21, 2011 /PRNewswire via COMTEX/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) announced today that the Company finished the 3rd Quarter strong with sales revenues during the three months ended September 30, 2011 in the amount of $86,717.40. The revenue for the third quarter is a result of instrument sales to over sixty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.
Solos Breast Endoscopy component sales accounted for approximately 39.5% of the total sales revenue for the third quarter or $34,290. The MammoView? instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView? Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.
"We're proud of our efforts during the 3rd Quarter, and we anticipate continued sales growth as we finish out the year," stated Bob Segersten, President of Solos Endoscopy, Inc.
The Company recently announced its intentions to donate 5% of its sales from the MammoView? Breast Endoscopy Instrument line for the month of October to support breast cancer awareness through education and early detection. The Company expects to post its full unaudited financial results for the quarter ended September 30, 2011 on the OTC Markets Group website within in the next thirty days.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
CONTACT: Amanda Segersten
rsegersten@solosendoscopy.com
SOURCE Solos Endoscopy, Inc.
www.prnewswire.com
Copyright (C) 2011 PR Newswire. All rights reserved
-0-
KEYWORD: Massachusetts
INDUSTRY KEYWORD: HEA
MTC
MEQ
OTC
SUBJECT CODE: SLS
o/s 304,897,710 according to this post http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67975300
float 70,416,215 (need confirmation)
a/s 500,000,000
Recent News
BOSTON, Oct. 21, 2011 /PRNewswire via COMTEX/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) announced today that the Company finished the 3rd Quarter strong with sales revenues during the three months ended September 30, 2011 in the amount of $86,717.40. The revenue for the third quarter is a result of instrument sales to over sixty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.
Solos Breast Endoscopy component sales accounted for approximately 39.5% of the total sales revenue for the third quarter or $34,290. The MammoView? instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView? Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.
"We're proud of our efforts during the 3rd Quarter, and we anticipate continued sales growth as we finish out the year," stated Bob Segersten, President of Solos Endoscopy, Inc.
The Company recently announced its intentions to donate 5% of its sales from the MammoView? Breast Endoscopy Instrument line for the month of October to support breast cancer awareness through education and early detection. The Company expects to post its full unaudited financial results for the quarter ended September 30, 2011 on the OTC Markets Group website within in the next thirty days.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
CONTACT: Amanda Segersten
rsegersten@solosendoscopy.com
SOURCE Solos Endoscopy, Inc.
www.prnewswire.com
Copyright (C) 2011 PR Newswire. All rights reserved
-0-
KEYWORD: Massachusetts
INDUSTRY KEYWORD: HEA
MTC
MEQ
OTC
SUBJECT CODE: SLS
My posts and comments are my opinions and they should not be used as investment advice. Always do a proper due diligence before making any investment.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
